Axsome Change To Liabilities from 2010 to 2024

AXSM Stock  USD 86.95  3.78  4.17%   
Axsome Therapeutics Change To Liabilities yearly trend continues to be very stable with very little volatility. Change To Liabilities is likely to grow to about 30.7 M this year. During the period from 2010 to 2024, Axsome Therapeutics Change To Liabilities quarterly data regression pattern had range of 31.4 M and standard deviation of  11,709,572. View All Fundamentals
 
Change To Liabilities  
First Reported
2013-12-31
Previous Quarter
11.2 M
Current Value
-13.9 M
Quarterly Volatility
6.5 M
 
Yuan Drop
 
Covid
Check Axsome Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Axsome Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 7.2 M, Interest Expense of 6.8 M or Selling General Administrative of 234 M, as well as many indicators such as Price To Sales Ratio of 12.69, Dividend Yield of 0.0 or PTB Ratio of 19.88. Axsome financial statements analysis is a perfect complement when working with Axsome Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Axsome Therapeutics Correlation against competitors.
To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.

Latest Axsome Therapeutics' Change To Liabilities Growth Pattern

Below is the plot of the Change To Liabilities of Axsome Therapeutics over the last few years. It is Axsome Therapeutics' Change To Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Axsome Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Change To Liabilities10 Years Trend
Slightly volatile
   Change To Liabilities   
       Timeline  

Axsome Change To Liabilities Regression Statistics

Arithmetic Mean7,050,552
Coefficient Of Variation166.08
Mean Deviation9,550,422
Median631,000
Standard Deviation11,709,572
Sample Variance137.1T
Range31.4M
R-Value0.74
Mean Square Error67.5T
R-Squared0.54
Significance0
Slope1,929,212
Total Sum of Squares1919.6T

Axsome Change To Liabilities History

202430.7 M
202329.3 M
202225.5 M
2021227.2 K
2020324.8 K
201914.4 M
20181.4 M

About Axsome Therapeutics Financial Statements

Axsome Therapeutics investors utilize fundamental indicators, such as Change To Liabilities, to predict how Axsome Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Change To Liabilities29.3 M30.7 M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Axsome Therapeutics is a strong investment it is important to analyze Axsome Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Axsome Therapeutics' future performance. For an informed investment choice regarding Axsome Stock, refer to the following important reports:
Check out the analysis of Axsome Therapeutics Correlation against competitors.
To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.
You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Axsome Therapeutics. If investors know Axsome will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Axsome Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(6.58)
Revenue Per Share
7.108
Quarterly Revenue Growth
0.813
Return On Assets
(0.26)
Return On Equity
(1.72)
The market value of Axsome Therapeutics is measured differently than its book value, which is the value of Axsome that is recorded on the company's balance sheet. Investors also form their own opinion of Axsome Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Axsome Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Axsome Therapeutics' market value can be influenced by many factors that don't directly affect Axsome Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Axsome Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Axsome Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Axsome Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.